DXCM · DexCom, Inc.
$62.222026-05-17Sector: Healthcare; Industry: Medical - Devices; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$58
-6.3% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($43 · $60) Analysts Range ($72 · $95) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $2.4B | — | 12.9% | 12.4% | $276MM | −$621MM | −$344MM | 10.8% | — | 9.2% | $3.0B | $0.54 | — |
| 2022.Q4 | $2.9B | 18.8% | 15.9% | 12.7% | $405MM | −$269MM | $136MM | 11.0% | — | 13.5% | $3.0B | $0.86 | — |
| 2023.Q4 | $3.6B | 24.5% | 19.6% | 23.8% | $540MM | −$191MM | $350MM | 10.6% | — | 17.4% | $3.2B | $1.36 | — |
| 2024.Q4 | $4.0B | 11.3% | 17.6% | 18.7% | $578MM | −$189MM | $390MM | 11.2% | — | 17.2% | $3.5B | $1.44 | — |
| 2025.Q4 | $4.7B | 15.6% | 23.2% | 23.2% | $831MM | −$178MM | $653MM | 11.4% | — | 23.1% | $3.7B | $2.10 | 22.9 |
| italics below = DCF projection · 10yr Rev CAGR: 10.7% |
| 2026.Q4 | $5.2B | +12.1% | 27.5% | 22.9% | $1.1B | −$461MM | $649MM | 9.7% | $592MM | 28.5% | $4.1B | $1.98 | 31.4 |
| 2027.Q4 | $5.9B | +12.2% | 26.2% | 22.5% | $1.2B | −$539MM | $652MM | 9.6% | $543MM | 27.1% | $4.7B | $2.19 | 28.4 |
| 2028.Q4 | $6.6B | +12.0% | 24.9% | 22.2% | $1.3B | −$620MM | $654MM | 9.5% | $497MM | 25.6% | $5.3B | $2.41 | 25.8 |
| 2029.Q4 | $7.5B | +13.9% | 23.6% | 21.9% | $1.4B | −$835MM | $546MM | 9.3% | $380MM | 24.2% | $6.1B | $2.71 | 23.0 |
| 2030.Q4 | $8.6B | +14.9% | 21.1% | 21.6% | $1.4B | −$1.1B | $355MM | 9.2% | $226MM | 21.3% | $7.2B | $3.00 | 20.7 |
|
| Term. Yr+ | $13.4B | 4.1% | 21.1% | 20.0% | $2.3B | −$490MM | $1.8B | 8.6% | $16.3B | 18.9% | — | — | — |
Active scenario IV: $58 (-6.3% vs market)